Illumina Selected to Sequence 450,000 Genomes for Singapore's SG-INSIGHT Study
Published
Illumina, a US company listed on the Nasdaq stock exchange under the ticker ILMN, has been chosen to provide whole-genome sequencing services for SG-INSIGHT, a large research study in Singapore. The company announced the selection, which covers the sequencing of 450,000 genomes.
Whole-genome sequencing is a method that reads almost all of a person's DNA, the genetic material that carries instructions for how the body develops and works. Scientists use this information to study how genes may be linked to health conditions and to diseases. Because the process can produce very large amounts of data, it requires advanced equipment and computer systems.
The announcement describes SG-INSIGHT as a cohort study, which means researchers follow a large group of people over time to look for patterns in health and genetics. The initial announcement did not include full details about the study's goals, timeline or funding, so these remain unclear for now.
The project shows how genetic research continues to grow in Singapore. As the work moves forward, more information about the study and its results may become available to the public.
Sources: BioPharma APAC
More Singapore news
- Singapore Needs More Tech Companies to Grow Its Stock Market, HSBC Strategist Says
- Singapore Tech Shares Rebound After Last Week's Sell-Off
- Databricks Plans to Double Its Singapore Team to 500 Staff
- Visa Sets Up Six Technology Hubs in New Singapore Centre
- US Congress Faces Possible Impeachment Fight Over Defence Secretary Pete Hegseth
- Giving Former Politicians Room to Return to Normal Life in Singapore
- Singapore Cloud Firm Megaspeed Faces Renewed US Scrutiny
- Iran Calls for Stronger Economic and Trade Ties with Singapore